Advertisement

Topics

Pembrolizumab Plus Chemotherapy Tied to Improved Survival in Lung Cancer

20:45 EDT 16 Apr 2018 | NEJM

Pembrolizumab immunotherapy can help extend life in patients with non-small-cell lung cancer (NSCLC) when added to standard chemotherapy, according to an industry-conducted...

Original Article: Pembrolizumab Plus Chemotherapy Tied to Improved Survival in Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "Pembrolizumab Plus Chemotherapy Tied to Improved Survival in Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...